WHA

Blujepa (gepotidacin)

Indications for Prior Authorization

Blujepa (gepotidacin)
  • For diagnosis of Uncomplicated Urinary Tract Infections
    Indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escheria coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis

Criteria

Blujepa

Prior Authorization

Length of Approval: 5 Day(s)

  • Diagnosis of an uncomplicated urinary tract infection (uUTI)
    • AND
  • Patient is 12 years of age or older
    • AND
  • Patient weighs at least 40kg
    • AND
  • Trial and inadequate response, contraindication or resistance to one alternative oral antibacterial treatment option (e.g., nitrofurantoin, trimethoprim-sulfamethoxazole, ciprofloxacin)
    • AND
  • Infection is caused by one of the following: [A]
    • Escherichia coli
    • Klebsiella pneumoniae
    • Citrobacter freundii complex
    • Staphylococcus saprophyticus
    • Enterococcus faecalis

  • Guideline ID
    GL-414194

  • Formulary
    Premium

  • Effective date
    Dec 1, 2025

  • P&T approval date
    Nov 20, 2025

P & T Revisions

1970-01-01

  1. Blujepa Prescribing Information. GlaxoSmithKline. March 2025.
  2. Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741-755. doi:10.1016/S0140-6736(23)02196-7
  3. American Urological Association. Adult UTI. Available at: https://www.auanet.org/meetings-and-education/for-medical-students/medical-students-curriculum/adult-uti. Accessed June 27, 2025.
  4. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257
  1. Similar to other antibacterial drugs, gepotidacin should only be used to treat uncomplicated UTIs that are proven or strongly suspected to be caused by the approved susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain efficacy of gepotidacin. [1, 4]